The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: Results of the German KIMS database

Growth Hormone and IGF Research

Volumn 21, Issue 1, 2011, Pages 1-10

  Spielhagen, Christin ^a   Schwahn, Christian ^a   Möller, Kristin ^a   Friedrich, Nele ^a   Kohlmann, Thomas ^a   Moock, Jörn ^a   Koätowska Häggström, Maria ^b   Nauck, Matthias ^a   Buchfelder, Michael ^c   Wallaschofski, Henri ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Growth hormone deficiency (GHD); IGF I; KIMS Germany; Long term GH replacement therapy; Quality of life (QoL)

Indexed keywords

CHOLESTEROL; GLUCOSE; GROWTH HORMONE; HYPOPHYSIS HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C;

ADULT; ARTHRALGIA; ARTICLE; BODY MASS; CARPAL TUNNEL SYNDROME; CENTRAL NERVOUS SYSTEM TUMOR; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HIP; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS TUMOR; HYPOPITUITARISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE;

ADULT; BODY WEIGHTS AND MEASURES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DWARFISM, PITUITARY; FEMALE; FOLLOW-UP STUDIES; GERMANY; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; QUALITY OF LIFE; RISK ASSESSMENT; TIME FACTORS; YOUNG ADULT;

EID: 79951726718     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.10.005     Document Type: Article

References (57)

1. Bates A.S., Van't Hoff W., Jones P.J., Clayton R.N. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996, 81:1169-1172.
2. Rosen T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336:285-288.
3. Markussis V., Beshyah S.A., Fisher C., Sharp P., Nicolaides A.N., Johnston D.G. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992, 340:1188-1192.
4. Wüster C., Slenczka E., Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?. Klin Wochenschr 1991, 69:769-773.
5. Beshyah S.A., Freemantle C., Thomas E., Rutherford O., Page B., Murphy M., et al. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol 1995, 42:179-189. (Oxf).
6. Jorgensen J.O., Pedersen S.A., Thuesen L., Jorgensen J., Ingemann-Hansen T., Skakkebaek N.E., et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989, 1:1221-1225.
7. Cuneo R.C., Salomon F., Wiles C.M., Hesp R., Sonksen P.H. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 1991, 70:695-700.
8. McGauley G.A., Cuneo R.C., Salomon F., Sonksen P.H. Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm Res 1990, 33(Suppl 4):52-54.
9. Rosen T., Wiren L., Wilhelmsen L., Wiklund I., Bengtsson B.A. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol 1994, 40:111-116. (Oxf).
10. Gibney J., Wallace J.D., Spinks T., Schnorr L., Ranicar A., Cuneo R.C., et al. The effects of 10years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999, 84:2596-2602.
11. Svensson J., Mattsson A., Rosen T., Wiren L., Johannsson G., Bengtsson B.A., et al. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Horm IGF Res 2004, 14:207-215.
12. Wallymahmed M.E., Foy P., Shaw D., Hutcheon R., Edwards R.H., MacFarlane I.A. Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3years. Clin Endocrinol (Oxf) 1997, 47:439-446.
13. Baum H.B., Biller B.M., Finkelstein J.S., Cannistraro K.B., Oppenhein D.S., Schoenfeld D.A., et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996, 125:883-890.
14. Götherström G., Svensson J., Koranyi J., Alpsten M., Bosaeus I., Bengtsson B., et al. A prospective study of 5years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001, 86:4657-4665.
15. Johannsson G., Rosen T., Bosaeus I., Sjostrom L., Bengtsson B.A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996, 81:2865-2873.
16. Beshyah S.A., Freemantle C., Thomas E., Johnston D.G. Comparison of measurements of body composition by total body potassium, bioimpedance analysis, and dual-energy X-ray absorptiometry in hypopituitary adults before and during growth hormone treatment. Am J Clin Nutr 1995, 61:1186-1194.
17. Cuneo R.C., Salomon F., Wiles C.M., Hesp R., Sonksen P.H. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991, 70:688-694.
18. Svensson J., Sunnerhagen K.S., Johannsson G. Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab 2003, 88:2061-2069.
19. al-Shoumer K.A., Gray R., Anyaoku V., Hughes C., Beshyah S., Richmond W., et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol 1998, 48:795-802. (Oxf).
20. Colao A., Di Somma C., Spiezia S., Savastano S., Rota F., Savanelli M.C., et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 2008, 93:3416-3424.
21. Svensson J., Fowelin J., Landin K., Bengtsson B.A., Johansson J.O. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002, 87:2121-2127.
22. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998, 83:379-381.
23. Clayton P.E., Cuneo R.C., Juul A., Monson J.P., Shalet S.M., Tauber M. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005, 152:165-170.
24. Svensson J., Bengtsson B.A., Rosen T., Oden A., Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004, 89:3306-3312.
25. Holmer H., Svensson J., Rylander L., Johannsson G., Rosen T., Bengtsson B.A., et al. Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone. J Clin Endocrinol Metab 2007, 92:3560-3567.
26. Chrisoulidou A., Beshyah S.A., Rutherford O., Spinks T.J., Mayet J., Kyd P., et al. Effects of 7years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000, 85:3762-3769.
27. Koltowska-Häggström M., Mattsson A.F., Monson J.P., Kind P., Badia X., Casanueva F.F., et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?. Eur J Endocrinol 2006, 155:109-119.
28. Koranyi J., Svensson J., Gotherstrom G., Sunnerhagen K.S., Bengtsson B., Johannsson G. Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study. J Clin Endocrinol Metab 2001, 86:4693-4699.
29. Mukherjee A., Tolhurst-Cleaver S., Ryder W.D., Smethurst L., Shalet S.M. The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy. J Clin Endocrinol Metab 2005, 90:1542-1549.
30. Rosilio M., Blum W.F., Edwards D.J., Shavrikova E.P., Valle D., Lamberts S.W., et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 2004, 89:1684-1693.
31. van der Klaauw A.A., Romijn J.A., Biermasz N.R., Smit J.W., van Doorn J., Dekkers O.M., et al. Sustained effects of recombinant GH replacement after 7years of treatment in adults with GH deficiency. Eur J Endocrinol 2006, 155:701-708.
32. Gilchrist F.J., Murray R.D., Shalet S.M. The effect of long-term untreated growth hormone deficiency (GHD) and 9years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol 2002, 57:363-370. (Oxf).
33. Götherström G., Bengtsson B.A., Bosaeus I., Johannsson G., Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007, 92:1442-1445.
34. Attanasio A.F., Bates P.C., Ho K.K., Webb S.M., Ross R.J., Strasburger C.J., et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database. J Clin Endocrinol Metab 2002, 87:1600-1606.
35. Malik I.A., Foy P., Wallymahmed M., Wilding J.P., MacFarlane I.A. Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. Clin Endocrinol 2003, 59:75-81. (Oxf).
36. Wiren L., Bengtsson B.A., Johannsson G. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol 1998, 48:613-620. (Oxf).
37. Hedeker D., Gibbons R.D. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Meth 1997, 2:64-78.
38. McKenna S.P., Doward L.C., Alonso J., Kohlmann T., Niero M., Prieto L., et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999, 8:373-383.
39. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
40. Abs R., Bengtsson B.A., Hernberg-Stahl E., Monson J.P., Tauber J.P., Wilton P., et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol 1999, 50:703-713. (Oxf).
41. Lie R.F., Schmitz J.M., Pierre K.J., Gochman N. Cholesterol oxidase-based determination, by continuous-flow analysis, of total and free cholesterol in serum. Clin Chem 1976, 22:1627-1630.
42. Lopes-Virella M.F., Stone P., Ellis S., Colwell J.A. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977, 23:882-884.
43. Singer J.D., Willett J.B. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence 2003, Oxford University Press, New York.
44. S. Rabe-Hesketh, A. Skrondal, A. Pickles. GLLAMM Manual.
45. Moock J., Albrecht C., Friedrich N., Völzke H., Nauck M., Koltowska-Haggstrom M. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania. Eur J Endocrinol 2009, 160:17-24. et al.
46. Verhelst J., Abs R., Vandeweghe M., Mockel J., Legros J.J., Copinschi G., et al. Two years of replacement therapy in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1997, 47:485-494.
47. Bengtsson B.A., Abs R., Bennmarker H., Monson J.P., Feldt-Rasmussen U., Hernberg-Stahl E., et al. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999, 84:3929-3935.
48. Burman P., Johansson A.G., Siegbahn A., Vessby B., Karlsson F.A. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997, 82:550-555.
49. Svensson J., Finer N., Bouloux P., Bevan J., Jonsson B., Mattsson A.F., et al. Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Horm IGF Res 2007, 17:67-76.
50. Meinhardt U.J., Ho K.K. Modulation of growth hormone action by sex steroids. Clin Endocrinol 2006, 65:413-422. (Oxf).
51. Franco C., Johannsson G., Bengtsson B.A., Svensson J. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency. J Clin Endocrinol Metab 2006, 91:4408-4414.
52. Lamberts S.W., van den Beld A.W., van der Lely A.J. The endocrinology of aging. Science 1997, 278:419-424.
53. Cutfield W.S., Wilton P., Bennmarker H., Albertsson-Wikland K., Chatelain P., Ranke M.B., et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000, 355:610-613.
54. Maison P., Griffin S., Nicoue-Beglah M., Haddad N., Balkau B., Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004, 89:2192-2199.
55. Svensson J., Bengtsson B.A. Safety aspects of GH replacement. Eur J Endocrinol 2009, 161:S65-S74.
56. Bengtsson B.A., Abs R., Feldt-Rasmussen U., Goth M., Monson J., Thunander M., Koltowska-Haggstrom M., et al. The risk of diabetes mellitus in hypopituitary patients on growth hormone substitution. Growth Horm IGF Res 2002, 12:302-303.
57. Attanasio A.F., Mo D., Erfurth E.M., Tan M., Ho K.Y., Kleinberg D., et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 2010, 95:74-81.